Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Atavistik Bio, Inc
Alterome Therapeutics, Inc.
ViroMissile, Inc.
Arcus Biosciences, Inc.
Tizona Therapeutics, Inc
Genentech, Inc.
Eli Lilly and Company
Jonsson Comprehensive Cancer Center
MacroGenics
Eli Lilly and Company
Innate Pharma
OncoNano Medicine, Inc.
City of Hope Medical Center
HiFiBiO Therapeutics
Rondo Therapeutics
Incyte Corporation
Actym Therapeutics, Inc.
Chongqing Precision Biotech Co., Ltd
Nurix Therapeutics, Inc.
Pfizer
Jonsson Comprehensive Cancer Center
University of Virginia
Incyte Corporation
NextPoint Therapeutics, Inc.
Zhejiang University
Turnstone Biologics, Corp.
Revolution Medicines, Inc.
Seagen Inc.
Seagen Inc.
Sotio Biotech Inc.
AstraZeneca
Molecular Templates, Inc.
NGM Biopharmaceuticals, Inc
The Affiliated Hospital of Qingdao University
Xencor, Inc.
Pliant Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
HRYZ Biotech Co.
University of Florida
Corvus Pharmaceuticals, Inc.
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd
Fate Therapeutics
Xencor, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
Ludwig Institute for Cancer Research
Revolution Medicines, Inc.